- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01172119
BioFreedom FIM Clinical Trial.
September 6, 2014 updated by: Biosensors Europe SA
A Prospective, Single Blinded, Randomized Study to Evaluate the Safety and Effictiveness of a Low and Standard Dose Biolimus A9TM Drug-Eluteing Coronary Stent Delivery System Compared With a TaxusTM LiberteTM Control Arm for Treatment of Stenotic Lesions in Native Coronary Arteries.
Prospective, multi center, randomized, single blinded study designed to demonstrate the safety and effectiveness of the Biosensors BioFreedom Drug-Eluting Coronary Stent Delivery System at multiple time points compared to the Taxus Liberte DES in the treatment of single de novo native coronary artery lesions ranging in diameter from ≥2.5 mm to ≤3.0 mm and ≤ 14 mm in length.
Study Overview
Status
Completed
Study Type
Interventional
Enrollment (Actual)
182
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamburg, Germany, D-22527
- Medical Care Center, Hamburg University Cardiovascular Center
-
Leipzig, Germany, D-04289
- Herzzentrum Leipzig GmbH
-
Siegburg, Germany, D-53721
- HELIOS - Klinikum Siegburg
-
Trier, Germany, D-54292 Trier
- Krankenhaus der Barmherzigen Brüder
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject is >18 years of age.
- The subject is an acceptable candidate for PTCA, stenting, and emergent CABG.
- Patients with multiple lesions as long as the last lesion to be treated fits the Inclusion criteria of the target lesion.
- The subject must have clinical evidence of ischemic heart disease or a positive functional study.
- The study stent target vessel must be a native coronary artery with a stenosis of >50% and <100%.
- The study stent target vessel reference diameter must be >2.5 mm and ≤ 3.0 mm.(Measurements may be made by careful visual estimate or on-line quantitative coronary angiography.)
- The study stent target lesion is a de novo lesion that has not been previously stented.
- The study stent target lesion must be ≤ 14 mm in length thus allowing for adequate lesion coverage with a single stent.
- The subject is male or, if female, is either not of childbearing potential or has had a negative pregnancy test within seven (7) days prior to the procedure.
- The subject or the subject's legal representative has been informed of the nature of the study and has provided written informed consent as approved by the Institutional Ethics Committee (IEC) of the clinical site.
- The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.
Exclusion Criteria:
- Multiple lesions to be treated in the same target vessel.
- Patients who require more than one BioFreedom stent except that an additional BioFreedom stent may be implanted in the target lesion for geographic miss or bailout
- A documented left ventricular ejection fraction < 30% assessed within 6 months prior to procedure by echocardiography, during a previous angiography or as measured during pre-procedure angiography.
- A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticlopidine and, clopidogrel, stainless steel, Biolimus A9, Paclitaxel or a sensitivity to contrast media, which cannot be adequately pre-medicated.
- A platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or a WBC <3,000 cells/mm³.
- Evidence of an acute myocardial infarction within 72 hours of the intended treatment (defined as: Q wave or non-Q wave infarction having CK enzymes > 2 times the upper laboratory normal with the presence of a CK-MB elevated above the institutions upper limit of normal).
- A previous coronary interventional procedure was performed either a.) within 24 hours prior to the procedure or b.) within 12 months prior to the procedure for any lesion in the target vessel.
- The subject requires planned interventional treatment of any lesion in either the target vessel within 12 months or in any non-target vessel within 30 days post-procedure.
- The target and non-target lesion require treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).
- The target vessel has angiographic evidence of thrombus or is excessively (2 bends > 90º to reach the target lesion) tortuous.
The target lesion has any of the following characteristics:
- Lesion location is aorto-ostial, left main coronary artery, or within 5 mm of the origin of the LAD, LCX, or RCA.
- Is at a >45º bend in the vessel.
- Is moderately to severely calcified (visible by fluoro).
- Stenting of the target or non-target lesion would "jail" or cover a side branch >2.0 mm in diameter or occur at the ostium of the sidebranch.
- History of a stroke or transient ischemic attack (TIA) within the prior 6 months or permanent neurologic deficit.
- History of upper GI bleeding within the prior 6 months.
- The subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- Concurrent medical condition with a life expectancy of less than 18 months.
- Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. [Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.]
- Any contraindications as mentioned in the TaxusTM LiberteTM Instructions for Use (IFU).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BioFreedom Standard Dose
|
Biofreedom DES with a standard dose of Biolimus A9TM
Biofreedom DES with a low dose of Biolimus A9TM
|
EXPERIMENTAL: BioFreedom Low Dose
|
Biofreedom DES with a standard dose of Biolimus A9TM
Biofreedom DES with a low dose of Biolimus A9TM
|
ACTIVE_COMPARATOR: Taxus Liberte drug eluting stents
|
Standard paclitaxel dose Taxus Liberte DES
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
In-Stent Late Lumen Loss at 12 months post-procedure.
Time Frame: 12 Months
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
In-Stent Late Lumen Loss (LL) at 4 months post-procedure for patients receiving IVUS/Angio at 4 months
Time Frame: 4 months
|
4 months
|
2. Major adverse cardiac events (MACE) at 30 days, defined as death, myocardial infarction or ischemic target vessel revascularization (PCI or CABG).
Time Frame: 30 days
|
30 days
|
3. Major Adverse Cardiac Event (MACE) at hospital discharge, 30 days, 4 months, 12 months, and 2, 3, 4 and 5 years post-procedure.
Time Frame: 5 years
|
5 years
|
Vascular complications through hospital discharge.
Time Frame: 5 years
|
5 years
|
5. Rates of stent thrombosis, per ARC definition of definite and probable and categorized as early, late or very late, at 30 days, 4 and 12 months, 2, 3, 4 and 5 years post-procedure.
Time Frame: 5 years
|
5 years
|
6. Biolimus A9 drug systemic drug levels post-procedure, 4 hours post-procedure, at hospital discharge, and at 30 days and 4 months clinical follow-up.
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eberhard Grube, Prof Dr med, Department of Cardiology Hospital Alemao O. Cruz, Sao Paulo, Brazil
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (ACTUAL)
June 1, 2010
Study Completion (ACTUAL)
July 1, 2014
Study Registration Dates
First Submitted
July 28, 2010
First Submitted That Met QC Criteria
July 28, 2010
First Posted (ESTIMATE)
July 29, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 9, 2014
Last Update Submitted That Met QC Criteria
September 6, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 08EU01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment Of Stenotic Lesions In Native Coronary Arteries.
-
Medinol Ltd.Completedde Novo Stenotic Lesions in Native Coronary ArteriesUnited States
-
Biotronik AGCompletedde Novo Lesions in Native Coronary ArteriesNetherlands, Switzerland, Germany, Belgium
-
Tryton Medical, Inc.CompletedCoronary Atherosclerosis of Native Coronary Artery | Bifurcation Lesions: de Novo Lesions of the Main and Side Branch of Native Coronary ArteryUnited States
-
Tel-Aviv Sourasky Medical CenterCompletedConsecutive Subjects Who Are Suitable for a Coronary | Angioplasty of de Novo Lesion(s) in Native Coronary | Arteries Should be Screened for Eligibility. | A Total Number of 200 Patients Fulfilling the Selection | Criteria and Willing to Sign the Informed Consent Should | be Enrolled in the...Israel
-
Biotronik (Beijing) Medical Device Ltd.Biotronik AGEnrolling by invitationNative Coronary Artery Stenosis | In-Stent Stenosis (Restenosis) of Coronary Artery StentChina
-
National Cancer Institute (NCI)CompletedHIV Infection | Clear Cell Renal Cell Carcinoma | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditionsUnited States
Clinical Trials on Biofreedom Drug Eluting Stent
-
Yonsei UniversityRecruitingAcute Coronary SyndromeKorea, Republic of
-
Medtronic VascularCompletedCoronary Artery DiseaseKorea, Republic of, Spain, Australia, Hong Kong, United Kingdom, Singapore, Thailand, Belgium, New Zealand, Sweden, France, Switzerland, Netherlands, Italy, Slovakia, Lithuania, Austria, Malaysia, Bulgaria, Ireland, Latvia, Norway, ...
-
Biosensors Europe SAUnknownIschemic Heart Disease | Stable Angina | Unstable Angina | Silent IschemiaUnited States
-
Seoul National University Bundang HospitalKorea University Anam Hospital; Korea University Guro Hospital; Gachon University... and other collaboratorsCompletedMyocardial Ischemia | Coronary Artery DiseaseKorea, Republic of
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Fatebenefratelli and Ophthalmic HospitalCompletedCardiovascular Diseases
-
Aarhus University Hospital SkejbyMedtronic Cardiovascular; Biosensors InternationalCompletedCoronary Artery Disease | Angina PectorisDenmark
-
Hospital Universitari Vall d'Hebron Research InstituteB.Braun Surgical SACompleted
-
Medtronic VascularMedtronic Japan Co., Ltd.CompletedMyocardial Ischemia | Cardiovascular Diseases | Coronary Artery Disease | Arterial Occlusive DiseasesJapan
-
Boston Scientific CorporationLabcoat, Ltd.CompletedCoronary Artery DiseaseItaly